SELLAS Life Sciences Group, Inc. (FRA:RXK3)
1.286
+0.058 (4.72%)
At close: Nov 28, 2025
FRA:RXK3 Statistics
Total Valuation
FRA:RXK3 has a market cap or net worth of EUR 183.79 million. The enterprise value is 146.18 million.
| Market Cap | 183.79M |
| Enterprise Value | 146.18M |
Important Dates
The next estimated earnings date is Wednesday, March 18, 2026.
| Earnings Date | Mar 18, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 142.44M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +82.98% |
| Shares Change (QoQ) | +9.98% |
| Owned by Insiders (%) | 0.26% |
| Owned by Institutions (%) | 23.15% |
| Float | 142.07M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | 4.73 |
| P/TBV Ratio | 4.93 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -6.61 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 8.28, with a Debt / Equity ratio of 0.01.
| Current Ratio | 8.28 |
| Quick Ratio | 7.48 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -84.33% and return on invested capital (ROIC) is -55.90%.
| Return on Equity (ROE) | -84.33% |
| Return on Assets (ROA) | -44.90% |
| Return on Invested Capital (ROIC) | -55.90% |
| Return on Capital Employed (ROCE) | -61.44% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -1.47M |
| Employee Count | 15 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +17.12% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +17.12% |
| 50-Day Moving Average | 1.50 |
| 200-Day Moving Average | 1.40 |
| Relative Strength Index (RSI) | 47.51 |
| Average Volume (20 Days) | 1,865 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 8.97 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -23.90M |
| Pretax Income | -22.11M |
| Net Income | -22.11M |
| EBITDA | n/a |
| EBIT | -23.90M |
| Earnings Per Share (EPS) | -0.24 |
Balance Sheet
The company has 37.77 million in cash and 510,528 in debt, giving a net cash position of 37.26 million.
| Cash & Cash Equivalents | 37.77M |
| Total Debt | 510,528 |
| Net Cash | 37.26M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 38.89M |
| Book Value Per Share | 0.31 |
| Working Capital | 36.76M |
Cash Flow
| Operating Cash Flow | -26.10M |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
FRA:RXK3 does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -82.98% |
| Shareholder Yield | -82.98% |
| Earnings Yield | -12.03% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on November 8, 2019. It was a reverse split with a ratio of 0.02.
| Last Split Date | Nov 8, 2019 |
| Split Type | Reverse |
| Split Ratio | 0.02 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |